Association between Symptoms of Depression and Generalised Anxiety Disorder Evaluated through PHQ-9 and GAD-7 and Anti-Obesity Treatment in Polish Adult Women.

Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI Publishing

Obesity*/psychology ; Obesity*/drug therapy ; Anxiety Disorders*/drug therapy ; Depression*/drug therapy; Humans ; Female ; Adult ; Middle Aged ; Poland ; Anti-Obesity Agents/therapeutic use ; Glucagon-Like Peptides/therapeutic use ; Anxiety/drug therapy ; Patient Health Questionnaire ; Young Adult ; Bariatric Surgery ; Body Mass Index ; Surveys and Questionnaires

Obesity impacts mental health greatly. Psychological factors may influence the effectiveness of its treatment. This study aimed to compare symptoms of generalised anxiety disorder and depression among adult women across different weight categories. The study sample comprised 1105 adult women. The computer-assisted web interview (CAWI) utilising the seven-item Generalised Anxiety Disorders Scale (GAD-7) and the nine-item Patient Health Questionnaire (PHQ-9) was used. Both GAD-7 and PHQ-9 scores correlated positively with BMI (r = 0.121, p < 0.001 and r = 0.173, p < 0.001, respectively) and negatively with age (r = -0.106, p < 0.001 and r = -0.103, p < 0.001, respectively). Patients undergoing treatment with semaglutide scored lower for both anxiety symptoms (8.71 ± 6.16, p = 0.013) and depression symptoms (9.76 ± 6.37, p = 0.013). Women who underwent bariatric surgery screened less frequently for anxiety (8.03 ± 6.27, p = 0.002) but not for depression. An interdisciplinary approach involving mental health professionals within the therapeutic team can comprehensively address factors contributing to obesity development and treatment outcomes. Further investigation of semaglutide's use is needed due to the promising evidence suggesting a positive effect on decreasing the severity of depression and anxiety symptoms to assess the direct or indirect character of this influence.

Obes Rev. 2023 Mar;24(3):e13543. (PMID: 36579723)
Br J Psychiatry. 2017 Jul;211(1):14-21. (PMID: 28428339)
Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. (PMID: 28386912)
SSM Popul Health. 2019 May 10;7:100405. (PMID: 31193386)
Front Psychol. 2021 Sep 21;12:712567. (PMID: 34646201)
JCI Insight. 2020 Mar 26;5(6):. (PMID: 32213703)
Am J Emerg Med. 2019 Apr;37(4):766-767. (PMID: 30098835)
Ann Med. 2018 Nov;50(7):605-612. (PMID: 30101619)
J Psychiatry Neurosci. 2021 Apr 20;46(2):E313-E318. (PMID: 33876735)
Br Med J. 1976 Jan 3;1(6000):7-9. (PMID: 1247732)
Gynecol Endocrinol. 2019 Feb;35(2):142-145. (PMID: 30599799)
Arch Intern Med. 2006 May 22;166(10):1092-7. (PMID: 16717171)
Psychoneuroendocrinology. 2017 Mar;77:112-121. (PMID: 28027497)
Front Psychiatry. 2018 Aug 23;9:390. (PMID: 30190687)
Arch Gen Psychiatry. 2010 Mar;67(3):220-9. (PMID: 20194822)
J Affect Disord. 2019 Feb 15;245:145-151. (PMID: 30388557)
Psychoneuroendocrinology. 2019 Dec;110:104425. (PMID: 31542635)
Ann Nutr Metab. 2015;66 Suppl 2:7-12. (PMID: 26045323)
Obes Surg. 2010 Feb;20(2):161-7. (PMID: 18958537)
Front Nutr. 2023 Oct 09;10:1287783. (PMID: 37876616)
Obes Rev. 2014 Jun;15(6):504-15. (PMID: 24661566)
Cureus. 2022 Jun 4;14(6):e25651. (PMID: 35784972)
Appetite. 2013 Jan;60(1):187-192. (PMID: 23046706)
Depress Anxiety. 2015 Sep;32(9):664-70. (PMID: 26047492)
Cureus. 2022 Feb 28;14(2):e22711. (PMID: 35386146)
Neurosci Biobehav Rev. 2022 Aug;139:104758. (PMID: 35777578)
Int J Mol Sci. 2020 Sep 07;21(18):. (PMID: 32906843)
Obes Facts. 2016;9(6):424-441. (PMID: 28013298)
EClinicalMedicine. 2023 Mar 20;58:101882. (PMID: 36992862)
Int J Obes (Lond). 2009 Feb;33(2):257-66. (PMID: 19125163)
Front Psychiatry. 2023 Aug 29;14:1238353. (PMID: 37706035)
Body Image. 2024 Sep;50:101727. (PMID: 38797069)
J Affect Disord. 2020 Nov 1;276:45-52. (PMID: 32697715)
Int J Environ Res Public Health. 2022 Feb 09;19(4):. (PMID: 35206126)
Eurasian J Med. 2018 Jun;50(2):111-115. (PMID: 30002578)
Eur J Cardiovasc Nurs. 2015 Dec;14(6):516-24. (PMID: 25031311)
Psychoneuroendocrinology. 2019 Apr;102:216-224. (PMID: 30590339)
Sleep. 2010 Feb;33(2):161-7. (PMID: 20175399)
J Adolesc Health. 2024 Jul;75(1):127-132. (PMID: 38752964)
Diabetes Metab Res Rev. 2021 Nov;37(8):e3458. (PMID: 33891377)
Brain Behav Immun. 2020 Jul;87:901-909. (PMID: 32113908)
Cureus. 2022 Feb 2;14(2):e21841. (PMID: 35291524)
Front Endocrinol (Lausanne). 2023 Nov 02;14:1283621. (PMID: 38027159)
Qual Health Res. 2020 Nov;30(13):2146-2159. (PMID: 32564676)
Nat Med. 2024 Jan;30(1):168-176. (PMID: 38182782)
Soc Psychiatry Psychiatr Epidemiol. 2018 Jun;53(6):629-638. (PMID: 29644388)
Neuropsychiatr. 2019 Jun;33(2):72-89. (PMID: 30778841)
Depress Res Treat. 2011;2011:194732. (PMID: 21977317)
Int J Clin Pharm. 2024 Apr;46(2):488-495. (PMID: 38265519)
Am J Public Health. 2000 Feb;90(2):251-7. (PMID: 10667187)
Women Health. 2008;48(4):467-84. (PMID: 19301534)
BMC Psychiatry. 2013 Jan 02;13:1. (PMID: 23281653)
Int J Obes (Lond). 2019 Jul;43(7):1391-1399. (PMID: 30258119)
J Affect Disord. 2023 Aug 1;334:213-219. (PMID: 37149049)
Obesity (Silver Spring). 2023 Jul;31(7):1913-1923. (PMID: 37368518)
Obesity (Silver Spring). 2014 Aug;22(8):1799-806. (PMID: 24634371)
J Affect Disord. 2022 Nov 15;317:287-297. (PMID: 36031002)
J Clin Med. 2020 Mar 23;9(3):. (PMID: 32210017)
Ind Psychiatry J. 2020 Jan-Jun;29(1):29-32. (PMID: 33776272)

SUBZ.C290.24.054 Wroclaw Medical University

Keywords: BMI; anxiety; depression; obesity; women health

53AXN4NNHX (semaglutide)
0 (Anti-Obesity Agents)
62340-29-8 (Glucagon-Like Peptides)

Date Created: 20240810 Date Completed: 20240810 Latest Revision: 20240918

20240918

PMC11314622

10.3390/nu16152438

39125320